Atopic dermatitis is one of the most common and welfare-significant conditions in dogs, causing chronic itch, skin damage, and secondary infection. Modern immunotherapy and targeted treatments have transformed the welfare outlook.
Atopic dermatitis welfare impact is primarily driven by chronic itch — a highly aversive sensation that disrupts sleep, prevents rest, and causes compulsive self-trauma. Dogs that scratch, chew, and rub continuously show signs of distress, and owners often underestimate the welfare significance of what they perceive as "just itching." The development of JAK inhibitors (oclacitinib) and anti-IL-31 monoclonal antibodies (lokivetmab) has transformed treatment — both provide rapid, safe itch relief that dramatically improves quality of life. Regular skin management including bathing with barrier-supportive shampoos, ear cleaning, and prompt treatment of secondary infections prevents welfare deterioration between treatment doses. Allergen-specific immunotherapy offers the possibility of long-term tolerance with reduced drug dependency. Identifying and avoiding specific allergen triggers through intradermal or serology testing personalises treatment. Weight management and stress reduction support skin barrier function as adjunctive measures.